Leading a First Clinical Trial as a Sponsor Organization
A company's first clinical trial is typically a leadership problem disguised as an operational one. The operational elements can be outsourced. The sponsor responsibilities cannot.
The most common misunderstanding is the scope of what remains with the sponsor after a CRO is engaged. Regulatory accountability does not transfer. Oversight obligations do not transfer. The decisions about protocol interpretation, eligibility judgments, safety communications, and whether a vendor's performance is acceptable all remain with the sponsor. A company running its first study frequently has no one whose job it is to make those critical decisions.
Three leadership priorities matter more than anything else in that first program.
Establish who holds sponsor decision authority, explicitly and in writing, before the first site is activated. In a small company this often lands with a single person who also has four other roles. That is workable if it is acknowledged and resourced. It is not workable if the authority is assumed and never defined, which is how questions from sites go unanswered for a week.
Build enough internal capability to evaluate the CRO's work rather than simply receive it. This does not require replicating the CRO's functions. It requires at least one person who can read a monitoring report critically, recognize when enrollment projections have been revised, and ask a data manager a question that produces a real answer. Without that, the sponsor is not overseeing anything.
Invest in the relationship before it is tested. The quality of a sponsor-CRO relationship during a crisis is largely determined by what was built beforehand. Governance meetings held consistently when things are fine are what make the difficult conversation productive when things are not.
First-time sponsors often assume that experience is the only thing separating them from established organizations. Experience matters, but the more immediate gap is structural. Defining decision rights, building minimum evaluative capability, and establishing governance discipline are all available to a first-time sponsor on day one, and they close much of the gap that affects outcomes.
